Ipsen Delivers Strong Sales Growth Of 18.8%1 In The First Half Of 2017 And Upgrades Its Guidance For Full Year 2017

Published: Jul 27, 2017

PARIS--(BUSINESS WIRE)--Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017.

H1 2017 Highlights

  • Strong operating performance of 18.8%1 Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales
  • Specialty Care sales growth of 23.1%1 reflects continued Somatuline® momentum and includes contribution of key new products Cabometyx® and Onivyde®
  • Consumer Healthcare sales growth of 1.3%1 including contribution of newly acquired products
  • Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%1, slight growth1 of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% of sales

Back to news